NEW YORK – Through a meta-analysis of pharmacogenomic studies, researchers in the US and Canada have found that genetic testing for CYP2C19 loss-of-function carrier status in patients with coronary artery disease (CAD) could help clinicians tailor anti-platelet treatments in order to reduce the risk of ischemic events.